JP2022509065A5 - - Google Patents

Info

Publication number
JP2022509065A5
JP2022509065A5 JP2021526658A JP2021526658A JP2022509065A5 JP 2022509065 A5 JP2022509065 A5 JP 2022509065A5 JP 2021526658 A JP2021526658 A JP 2021526658A JP 2021526658 A JP2021526658 A JP 2021526658A JP 2022509065 A5 JP2022509065 A5 JP 2022509065A5
Authority
JP
Japan
Prior art keywords
amino acid
cancer
sirpα
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021526658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509065A (ja
JP7451520B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/081523 external-priority patent/WO2020099653A1/en
Publication of JP2022509065A publication Critical patent/JP2022509065A/ja
Publication of JP2022509065A5 publication Critical patent/JP2022509065A5/ja
Application granted granted Critical
Publication of JP7451520B2 publication Critical patent/JP7451520B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021526658A 2018-11-15 2019-11-15 ヒト化抗SIRPα抗体 Active JP7451520B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18206594 2018-11-15
EP18206594.6 2018-11-15
PCT/EP2019/081523 WO2020099653A1 (en) 2018-11-15 2019-11-15 HUMANIZED ANTI-SIRPα ANTIBODIES

Publications (3)

Publication Number Publication Date
JP2022509065A JP2022509065A (ja) 2022-01-20
JP2022509065A5 true JP2022509065A5 (https=) 2022-11-02
JP7451520B2 JP7451520B2 (ja) 2024-03-18

Family

ID=64331834

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021526658A Active JP7451520B2 (ja) 2018-11-15 2019-11-15 ヒト化抗SIRPα抗体

Country Status (13)

Country Link
US (1) US12180295B2 (https=)
EP (1) EP3880707A1 (https=)
JP (1) JP7451520B2 (https=)
CN (1) CN113412279B (https=)
AU (1) AU2019378101B2 (https=)
BR (1) BR112021009275A2 (https=)
CA (1) CA3118966A1 (https=)
CL (1) CL2021001260A1 (https=)
IL (1) IL282756A (https=)
MX (1) MX2021005761A (https=)
MY (1) MY204673A (https=)
SG (1) SG11202104431PA (https=)
WO (1) WO2020099653A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL262251B2 (en) 2016-04-14 2023-09-01 Ose Immunotherapeutics New anti-syrap antibodies and their medical applications
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
AU2017371070B2 (en) 2016-12-09 2025-01-02 Alector Llc Anti-SIRP-alpha antibodies and methods of use thereof
KR102702926B1 (ko) * 2017-04-13 2024-09-06 사이로파 비.브이. 항-sirp 알파 항체
PE20201265A1 (es) 2018-03-21 2020-11-19 Alx Oncology Inc Anticuerpos contra proteina alfa reguladora de senal y metodos de uso
JP7337099B2 (ja) 2018-05-25 2023-09-01 アレクトル エルエルシー 抗sirpa抗体およびその使用法
AU2021378152A1 (en) * 2020-11-11 2023-06-22 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY
CN112574310B (zh) * 2020-12-11 2023-05-05 浙江博锐生物制药有限公司 抗SIRPα抗体及其用途
CN114790241B (zh) * 2021-01-26 2024-12-13 北京免疫方舟医药科技有限公司 抗tigit抗体及其应用
TW202317620A (zh) 2021-06-04 2023-05-01 德商百靈佳殷格翰國際股份有限公司 抗SIRPα抗體
EP4619435A1 (en) 2022-11-16 2025-09-24 Boehringer Ingelheim International GmbH Predictive efficacy biomarkers for anti-sirpa antibodies

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO2001040307A1 (de) 1999-11-30 2001-06-07 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper gegen signal-regulator-proteine
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
PE20090943A1 (es) 2007-07-16 2009-08-05 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
TR201908314T4 (tr) 2009-02-20 2019-06-21 2 Bbb Medicines B V Glutatyon bazlı ilaç dağıtım sistemi.
CN101880324B (zh) * 2010-05-25 2012-10-17 中国人民解放军第二军医大学 一种抗人SIRPα的单克隆抗体及其细胞株、制备方法和应用
US9403906B2 (en) 2011-01-19 2016-08-02 Cantargia Ab Method of treatment of a solid tumor with interleukin-1 accessory protein antibody
BR112013031762A2 (pt) * 2011-06-16 2016-09-13 Novartis Ag proteínas solúveis para utilização como terapêuticos
WO2013056352A1 (en) 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
WO2013150043A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
WO2013180200A1 (ja) 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
WO2014105910A1 (en) 2012-12-26 2014-07-03 Oncosynergy, Inc. ANTI- INTEGRIN β1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN103665165B (zh) * 2013-08-28 2016-02-24 江苏匡亚生物医药科技有限公司 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途
CN106456749B (zh) * 2014-03-11 2021-03-30 小利兰·斯坦福大学托管委员会 抗SIRPα抗体和双特异性巨噬细胞增强型抗体
PL3180363T3 (pl) * 2014-08-15 2020-02-28 Merck Patent Gmbh Białka fuzyjne immunoglobulin sirp-alfa
CN114425077A (zh) 2015-05-18 2022-05-03 起源生物医药公司 Sirp多肽组合物和使用方法
WO2017068164A1 (en) 2015-10-21 2017-04-27 Ose Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
BR112018070823A2 (pt) * 2016-04-14 2019-02-05 Ose Immunotherapeutics anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno.
CN109862910A (zh) 2016-08-03 2019-06-07 小利兰·斯坦福大学托管委员会 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
AU2017371070B2 (en) * 2016-12-09 2025-01-02 Alector Llc Anti-SIRP-alpha antibodies and methods of use thereof
KR102702926B1 (ko) 2017-04-13 2024-09-06 사이로파 비.브이. 항-sirp 알파 항체
CN118271443A (zh) * 2017-05-16 2024-07-02 拜奥迪斯私人有限公司 抗SIRPα抗体
BR112020001653A2 (pt) 2017-07-26 2020-07-21 Forty Seven, Inc. anticorpos anti-sirp-alfa e métodos relacionados

Similar Documents

Publication Publication Date Title
JP2022509065A5 (https=)
JP2021524249A5 (https=)
JP2020520370A5 (https=)
US11136413B2 (en) PDL-1 antibody, pharmaceutical composition thereof, and uses thereof
JP7840511B2 (ja) 抗クローディン18抗体及びそれらの使用の方法
JP7002467B2 (ja) 新規のb7‐h3結合分子、その抗体薬物コンジュゲート、及びその使用方法
CA2991880C (en) ANTIBODIES BINDING TO HUMAN CD3
KR102790232B1 (ko) Cd70 병용 요법
IL258202B2 (en) CD3-binding polypeptides, a method for their preparation, pharmaceutical preparations, nucleic acids, vectors and the use of such polypeptides
JP2022505871A5 (https=)
AU2018268304A1 (en) Anti-SIRPα antibodies
WO2024051796A1 (en) Albumin binding proteins, fusion proteins and uses thereof
CA3193662A1 (en) Pharmaceutical combination containing anti-pd-1-anti-vegfa bispecific antibody, and use thereof
JP2024515396A5 (https=)
CN103768596B (zh) 用于肿瘤治疗的组合产品、其用途及相关方法
RU2021116831A (ru) ГУМАНИЗИРОВАННЫЕ АНТИ-SIRPα АНТИТЕЛА
WO2025157223A1 (en) Multispecific antibodies and uses thereof
WO2025175056A1 (en) Multispecific antibodies or antigen binding fragments thereof to b7-h7 and immune effector cell antigens
CA3232304A1 (en) Use of anti-cd40 antibody
Schmielau et al. Clinical Studies In Oncology
HK40091003A (en) Pharmaceutical combination containing anti-pd-1-anti-vegfa bispecific antibody, and use thereof
HK40123160A (zh) 抗pd-1-抗vegfa的双特异性抗体的医药用途
HK40114665A (zh) 包含抗ctla4-抗pd-1双特异性抗体的药物组合及其用途
HK40064186A (en) Anti-claudin 18 antibodies and methods of use thereof
CN118615438A (zh) 包含抗ctla4-抗pd-1双特异性抗体的药物组合及其用途